Catalyst Pharmaceuticals, Inc.
CPRX
Rang in aandelen
#4165
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Aandeelprijs
$31.49
Laatst gesynchroniseerd: 2026-07-21
Marktkapitalisatie
$3.85B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
53.24%
Land
US
Handel Catalyst Pharmaceuticals, Inc. (CPRX)
Categorie
Healthcare
Operationele marge voor Catalyst Pharmaceuticals, Inc. (CPRX)
Operationele marge op October 2026 TTM: 44.83%
Volgens de meest recente financiële rapporten en aandelenkoers van Catalyst Pharmaceuticals, Inc. is de huidige operationele marge (TTM) 44.83%. Eind 2023 had het bedrijf een operationele marge van 21.80%.
Geschiedenis van de operationele marge van Catalyst Pharmaceuticals, Inc. van 2002 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 44.83% | 12.98% |
| 2024 | 39.68% | 82.02% |
| 2023 | 21.80% | -54.14% |
| 2022 | 47.54% | 27.80% |
| 2021 | 37.20% | 7.24% |
| 2020 | 34.69% | 11.51% |
| 2019 | 31.11% | -100.44% |
| 2018 | -7,059.03% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | -100.00% |
| 2010 | -823.01% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -99.14% |
US
|
|
| -149.01% | -103.32% |
US
|
|
| 25.57% | -99.43% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.36% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.